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Abstract
Network meta‐analysis (NMA) compares several interventions that are linked in a
network of comparative studies and estimates the relative treatment effects be-
tween all treatments, using both direct and indirect evidence. NMA is increasingly
used for decision making in health care, however, a user‐friendly system to evaluate
the confidence that can be placed in the results of NMA is currently lacking. This
paper is a tutorial describing the Confidence In Network Meta‐Analysis (CINeMA)
web application, which is based on the framework developed by Salanti et al (2014,
PLOS One, 9, e99682) and refined by Nikolakopoulou et al (2019, bioRxiv). Six
domains that affect the level of confidence in the NMA results are considered:
(a) within‐study bias, (b) reporting bias, (c) indirectness, (d) imprecision, (e) hetero-
geneity, and (f) incoherence. CINeMA is freely available and open‐source and no
login is required. In the configuration step users upload their data, produce network
plots and define the analysis and effect measure. The dataset should include
assessments of study‐level risk of bias and judgments on indirectness. CINeMA calls
the netmeta routine in R to estimate relative effects and heterogeneity. Users are
then guided through a systematic evaluation of the six domains. In this way re-
viewers assess the level of concerns for each relative treatment effect from NMA as
giving rise to “no concerns,” “some concerns,” or “major concerns” in each of the six
domains, which are graphically summarized on the report page for all effect
estimates. Finally, judgments across the domains are summarized into a single
confidence rating (“high,” “moderate,” “low,” or “very low”). In conclusion, the
user‐friendly web‐based CINeMA platform provides a transparent framework to
evaluate evidence from systematic reviews with multiple interventions.
1 | INTRODUCTION
Network meta‐analysis (NMA) is increasingly being used to make
decisions about optimal interventions in health care (Kanters
et al., 2016; Petropoulou et al., 2016). It combines direct evidence
from studies that directly compare two or more interventions, and
indirect evidence from studies that indirectly inform a comparison
through intermediate comparators. To evaluate the confidence in the
results of NMA, a framework has been developed (Salanti, Del
Giovane, Chaimani, Caldwell, & Higgins, 2014) and recently refined
(Nikolakopoulou et al., 2019), which is called CINeMA (Confidence In
Network Meta‐Analysis). The CINeMA framework considers six
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2020 The Authors. Campbell Systematic Reviews published by John Wiley & Sons Ltd on behalf of The Campbell Collaboration
domains that affect the level of confidence in the NMA results: (a)
within‐study bias, (b) reporting bias, (c) indirectness, (d) imprecision,
(e) heterogeneity, and (f) incoherence. Reviewers assess the level of
concerns for each relative treatment effect from NMA as giving rise
to “no concerns,” “some concerns,” or “major concerns” in each of the
six domains. Then, judgments across the domains are summarized
into a single confidence rating (“high,” “moderate,” “low,” or
“very low”).
The six domains include considerations pertaining to all stages of
the systematic review, including literature search, data extraction,
and statistical analysis. Within‐study bias domain refers to limitations
in the individual studies that may lead to a biased estimated relative
treatment effect. Reporting bias results from the inclusion in the
systematic review of a nonrepresentative set of the eligible studies,
that may occur for example from an uncomplete literature search.
Indirectness refers to the relevance of the included studies to the
research question, which includes the definition of the population,
interventions, and outcomes of interest. A core assumption in NMA is
that of transitivity; that there is an underlying true relative treatment
effect which applies to all studies regardless of the treatments being
compared. Assessment of transitivity is challenging and is usually
done by exploring the distribution of effect modifiers per compar-
ison. CINeMA's approach for indirectness intends to also address the
assumption of transitivity by indicating which comparisons may suf-
fer from different definitions of the setting of interest. Assuming that
transitivity holds implies that consistency—which refers to the
agreement of the estimated treatment effects—also holds. This can
be assessed under the incoherence domain in CINeMA. Finally, im-
precision and heterogeneity domains refer to the certainty with
which each effect is estimated and the variability in the results of
studies contributing to each comparison respectively.
The CINeMA framework has been implemented in a user‐
friendly web application (see https://cinema.ispm.unibe.ch/; CINe-
MA, 2017). From a technical point of view, CINeMA is a single page
application which communicates to an R back‐end server; in parti-
cular, the packages meta and netmeta are used (Rücker, Schwar-
zer, Krahn, & König, 2016; Schwarzer, 2019). It is developed as a
custom functional reactive framework and written in JavaScript and
PureScript. CINeMA does not permanently store the data, or any
other information related to the uploaded projects; only temporary
storage takes place for the sake of the calculations or network
efficiency. The source code of CINeMA can be found in
(Papakonstantinou).
The methodology described in (Nikolakopoulou et al., 2019) has
been implemented in CINeMA using “rules” that can automate de-
rivation of domain‐specific judgments. Three rules can be used to
summarize the risk of within‐study bias and of indirectness for each
relative effect estimate and produce automated judgments. Two le-
vels of judgment for reporting bias are suggested, based on com-
pleteness of the literature search, empirical studies, and statistical
analyses. The rules for judging imprecision and heterogeneity are
based on whether the confidence interval or prediction interval in-
cludes the line of no‐effect and prespecified clinically important
treatment effects. The use of rules is optional, and the outputs can be
partially or fully overridden. However, the semiautomated process
helps researchers to form judgments. Early applications of CINeMA
have appeared in the literature (Cipriani et al., 2018; Schwingshackl
et al., 2018).
Here we provide a tutorial describing the functionality of CI-
NeMA. We explain how the software works, the data formats and
requirements, the default options implemented in the rules, and their
rationale. We describe the functionality of CINeMA and illustrate its
use with the example of a NMA that compared the incidence of
diabetes in patients taking antihypertensive drugs or placebo. The
network included 22 randomized trials which evaluated the differ-
ences between angiotensin‐converting‐enzyme inhibitors (ACE),
angiotensin‐receptor blockers (ARB), calcium‐channel blocker (CCB),
Beta Blocker, diuretics, and placebo. The NMA found that the risk of
diabetes was lower with ARB, and higher with diuretics than with
placebo (Elliott and Meyer, 2007). In this example, data on study‐
level indirectness only serve to illustrate how the indirectness do-
main is assessed and do not reflect the relevance of each study to the
research question.
2 | UPLOADING DATA: MY PROJECTS
Under “My Projects,” users upload a .csv file with the study outcome
data for their project. The dataset should also include the data on the
study‐level risk of bias (RoB) and judgments on indirectness. Study‐
level RoB would normally summarize considerations on selection,
performance, attrition, detection, and reporting bias (Higgins
et al., 2011), while study‐level indirectness refers to deviations be-
tween the data and the targeted research question. Study‐level RoB
and indirectness can take either {1, 2, 3}, {l, m, h} or {L, M, H} values
for low, moderate, and high RoB and indirectness respectively.
The outcome can be binary or continuous and the format of the
data can be either long or wide. Currently, other types of outcomes,
for example, time to event or rate data, are not supported. In the long
format each row represents a study treatment arm. For example,
two‐arm studies occupy two rows, three‐arm studies occupy three
rows, and so on. In the wide format each row represents a study
treatment comparison. This corresponds to ( )T
2
rows for a T arm
study. For binary outcomes, number of events and sample size per
treatment arm and study should be provided. For continuous out-
comes, means, standard deviations, and sample size per treatment
arm and study are needed. Table 1 illustrates how binary and con-
tinuous outcomes can be imported using long or wide formats. For
example, binary outcome data on long format should be imported as
in Table 1a, providing at least six columns for the study id and the
treatment name, the events, the sample size, RoB and indirectness
per study arm. Table 1 can be used as a guide on how outcome data
of different possible formats can be used as input to CINeMA.
It might be that summary data are not available for each inter-
vention group for each study. In this situation data can be imported
in “inverse variance” format, where a comparison‐specific estimate of
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the relative treatment effect (assumed to follow a normal distribu-
tion) and its standard error are reported (e.g., log odds ratios, stan-
dardized mean differences, etc., see Table 2). When the “inverse
variance” format is used, CINeMA will prompt the user to define
whether the outcome is binary or continuous. Table 2 can be used as
a guide on how outcome data of “inverse variance” format can be
used as input to CINeMA.
Users should choose one of the five data formats in Tables 1
and 2. The names of variables can be as in Tables 1 or 2 (in which
case CINeMA will automatically recognize which column refers to
which variable) but custom field names are also allowed (e.g., “events”
instead of “r” for number of events in Table 1a). If custom field names
are used, CINeMA will prompt the user to specify which column
represents which field after uploading the dataset. Once the proce-
dure is done (or directly after uploading the data, if variable names
are exactly as in Tables 1 or 2), information on the file format (long,
wide), outcome type (binary, continuous), number of studies, number
of interventions, and number of comparisons with direct evidence
appears. Renaming the project's title is also possible under “Rename.”
Then, users can click on “Proceed” to go to “Configuration.”
2.1 | Worked example
Uploading the network of antihypertensive drugs, CINeMA re-
cognizes the file format (long) and outcome type (binary) and pro-
vides summary of the dataset: it includes 22 studies, 6 interventions,
and 14 comparisons with direct data.
3 | SETTING‐UP THE NMA: CONFIGURATION
The “Configuration” tab is activated once the dataset has been up-
loaded and variable names have been successfully defined. In this tab
the user needs to define the NMA analysis and is presented with a
network plot. This page also allows users to evaluate only a subset of
all possible intervention comparisons.
3.1 | Network plot
The network plot corresponding to the uploaded dataset is auto-
matically drawn with equally sized nodes and edges. Users can
choose to weight nodes and/or edges according to the sample size or
the number of studies (under “Node size by” and “Edge width by”).
TABLE 1 Examples of four possible data formats that can be used as input to CINeMA
Long format Wide format
Binary
Table 1a Table 1b
id t r n rob Indirectness id t1 r1 n1 t2 r2 n2 rob Indirectness
1 A 5 12 2 1 1 A 5 12 B 7 15 2 1
1 B 7 15 2 1 2 A 6 9 B 7 10 3 2
2 A 6 9 3 2 2 A 6 9 C 2 8 3 2
2 B 7 10 3 2 2 B 7 10 C 2 8 3 2
Continuous
Table 1c Table 1d
id t y sd n rob Indirectness id t1 y1 sd1 n1 t2 y2 sd2 n2 rob Indirectness
1 A 5 5 12 2 1 1 A 5 5 12 B 7 6 15 2 1
1 B 7 6 15 2 1 2 A 6 7 9 B 7 8 10 3 2
2 A 6 7 9 3 2 2 A 6 7 9 C 2 9 8 3 2
2 B 7 8 10 3 2 2 B 7 8 10 C 2 9 8 3 2
Note: Data should be imported as a .csv file. The displayed column names are the default expected names; if other names are provided CINeMA will return
a query. id specifies the study; t specifies the treatment (numeric or string); r is the number of events; n is the sample size; t1 and t2 specify the treatment
codes (numeric or string); r1 and r2 are the number of events in treatments t1 and t2; n1 and n2 are the sample sizes in treatments t1 and t2, respectively;
y is the mean; sd is the standard deviation; n is the sample size; y1 and y2 are the means in treatments t1 and t2; sd1 and sd2 are the standard deviations
in treatments t1 and t2; rob specifies risk of bias and indirectness specifies level of indirectness; rob and indirectness can take either 1, 2, and 3 or L, M, H
values for low, moderate, and high risk of bias or level of indirectness.
TABLE 2 Example of “inverse variance” data format in CINeMA
id t1 t2 effect se rob Indirectness
1 A B 0.5 0.3 2 1
2 B D 0.8 0.2 1 2
3 A 6 0.7 0.4 3 3
Note: Data should be imported as a .csv file. id specifies the study, t1 and
t2 specify the treatment codes (numeric or string), effect is the effect
estimate of t1 versus t2 which can be log odds ratio, log risk ratio, log
hazard ratio, mean difference or standardized mean difference, se is the
standard error of the effect estimate, rob specifies risk of bias, and
indirectness specifies level of indirectness; rob and indirectness can take
either 1, 2, and 3 or L, M, H values for low, moderate, and high risk of bias
or level of indirectness.
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Nodes can either be all blue or colored according to the proportion of
studies with low (green), moderate (yellow), and high (red) RoB or
indirectness (under “Node color by”). “Edge color by” dropdown menu
allows coloring edges according to the most prevalent bias level
within each comparison (“Majority RoB”), the average RoB of the
included studies (“Average RoB”), or the maximum bias level within
each comparison (“Highest RoB”); the respective categories for in-
directness are also available (“Majority Indirectness,” “Average In-
directness,” “Highest Indirectness”). Different representations may
be chosen according to users' interests: for example, “Highest RoB”
or “Highest Indirectness” could be chosen when users are interested
in viewing the worst pieces of evidence feeding into each compar-
ison. The network plot image can be exported as a .png file using the
“Save Plot” button. The outcome data appear next to the network
plot. By clicking on a specific edge or node, the respective outcome
data corresponding to that edge or node appear on the data table.
3.2 | Define your analysis
Here users are asked to choose whether to perform a fixed effect or
a random effects NMA (under “Analysis model”) and to define effect
measure type (under “Effect measure”). For binary outcomes, the
options “Odds Ratio,” “Risk Ratio,” and “Risk Difference” will appear,
and for continuous outcomes the options “Mean Difference” and
“Standardized Mean Difference.”
3.3 | Select intervention comparisons for evaluation
An NMA that compares several interventions produces estimates for
all possible relative effects. However, it can be the case that not all of
them are of interest (e.g., comparisons between placebo and older
drugs that are no longer used). CINeMA offers the option to select
which intervention comparisons are to be evaluated. Users should
first select the interventions of interest and then specify whether
they want to evaluate all the comparisons that contain these inter-
ventions (“Containing any of the above interventions”) or only the
comparisons that are formed between the selected interventions
(“Between the above interventions”). For example, in a network with
four interventions A, B, C, and D selecting A and B with the “Con-
taining any of the above interventions” option will result in evalua-
tion of comparisons AB, AC, AD, BC, and BD (all possible
comparisons except CD). Selecting A and B with “Between the above
interventions” option will result in evaluating a single comparison
(AB). A list of the comparisons to be evaluated then appears. Note
that the analysis is performed using all studies irrespective of whe-
ther a subset or all comparisons are evaluated.
After defining the comparisons for evaluation, the “Set up your
evaluation” button appears. Clicking on this performs two actions.
First, it calls netmeta in R to estimate all relative effects from the
network and a common heterogeneity parameter. The relative ef-
fects are found in the league table, which can be downloaded and
saved as a .csv file (“Download league table”). Second, it calls an R
function that calculates the contribution matrix (Papakonstantinou).
The contribution matrix shows the percentage contribution of in-
formation from each study and each direct comparison (shown in
columns) to the estimation of each relative effect (shown in rows). It
is calculated using the flow decomposition method described in
(Papakonstantinou et al., 2018) and is used later in the evaluation of
within‐study bias and indirectness. Users can download the output
in .csv format using options “Download per study contribution ma-
trix” or “Download per comparison contribution matrix.”
During evaluation, the user can abort computations by pressing
the “Cancel” button. Once calculations are done, the “Reset your
evaluation” button deletes all previous choices and computations.
“Proceed” saves the analysis (CINeMA will remember choices made
so far in the case of refreshing or closing and revisiting the page) and
takes users to the “Within‐study bias” domain.
3.4 | Worked example
The results of selecting different options for weighting the network
plot are shown in Figure 1. In the “Define your analysis” section, we
select a “Random effects” model and “Odds Ratio” as the effect
measure to be analyzed. We select all interventions to be evaluated;
note that in this case there is no difference between choosing
“Containing any of the above interventions” and choosing “Between
the above interventions.” Table 3 shows the downloaded league ta-
ble; per comparison and per study contribution matrices are given in
Appendix Tables A1 and A2.
4 | EVALUATING CONCERNS
4.1 | Within‐study bias
4.1.1 | RoB contributions
The number of studies at low, moderate, and high RoB appears on the
top of the page. CINeMA considers the per‐study contribution matrix
in conjunction with RoB assessments to evaluate each relative treat-
ment effect with respect to within‐study bias. A bar chart is drawn
under the “Risk of bias contributions” section; each bar corresponds to
an estimate of relative effect. Each bar also represents a reordering of
a column of the per‐study contribution matrix, where studies with low,
moderate, and high RoB have been grouped together and colored
accordingly. Each study is represented by a colored area with white
borders and is proportional to its contribution. Users can download
the bar chart as a .png file using the “Save Chart” button.
High RoB should be associated with “Major concerns,” moderate
RoB with “Some concerns,” and low RoB with “No concerns.” However,
for each relative effect a different combination of high, moderate, and
low RoB studies contribute to the estimate. Under the bar graph, a
dropdown menu offers three possible “rules” that can be used to
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summarize the RoB for each relative effect estimate and produce
automated judgments. Options include “Majority RoB,” “Average RoB,”
and “Highest RoB.” Choosing “Majority RoB” will lead to a level of
concern according to the RoB with the greatest total percentage
contribution (the greatest block between green, yellow, and red in
each bar). The “Highest RoB” will assign a level of concern determined
by the highest RoB in each bar. Summarizing RoB assessments using
“Average RoB” uses a weighted average score for each relative effect
estimate according to the percentage contribution of studies at each
bias level. For example, if the contributions from low (arbitrarily as-
signed a score of 1), moderate (score 2), and high (score 3) RoB studies
are 40%, 25%, and 35% respectively, the total RoB score will be
× + × + × =0.40 1 0.25 2 0.35 3 1.95 which rounds to 2 and leads
to “Some concerns.” In this example the judgment for “Majority RoB”
would be “No concerns” and for “Highest RoB” would be “Major
concerns.”
After selecting a rule, the boxes under the dropdown
menu—which correspond to the each estimate of relative
F IGURE 1 Network plot for the network meta‐analysis of antihypertensive drugs and diabetes incidence using four different sizing and
coloring combinations. Green, yellow, and red colors refer to low, moderate, and high risk of bias or indirectness. The plot can be downloaded as
a .png file by clicking on “Save Plot” in “Configuration.” ACE, angiotensin‐converting‐enzyme inhibitors; ARB, angiotensin‐receptor blockers;
BBlocker, Beta Blocker; CCB, calcium‐channel blocker
TABLE 3 NMA results from the network of antihypertensive drugs
ACE 1.070 (0.880, 1.300) 0.713 (0.614, 0.828) 0.846 (0.728, 0.983) 0.665 (0.566, 0.782) 0.885 (0.769, 1.017)
0.935 (0.769, 1.136) ARB 0.667 (0.557, 0.799) 0.791 (0.664, 0.942) 0.622 (0.504, 0.767) 0.827 (0.691, 0.990)
1.402 (1.208, 1.628) 1.500 (1.252, 1.797) Beta Blocker 1.186 (1.049, 1.341) 0.933 (0.789, 1.104) 1.240 (1.053, 1.461)
1.182 (1.017, 1.374) 1.264 (1.061, 1.507) 0.843 (0.746, 0.953) CCB 0.786 (0.670, 0.924) 1.046 (0.894, 1.224)
1.503 (1.279, 1.766) 1.608 (1.303, 1.983) 1.072 (0.906, 1.268) 1.272 (1.083, 1.493) Diuretic 1.330 (1.124, 1.573)
1.130 (0.983, 1.300) 1.209 (1.011, 1.447) 0.806 (0.684, 0.950) 0.956 (0.817, 1.119) 0.752 (0.636, 0.890) Placebo
Note: Odds ratios and their 95% confidence intervals are presented. Odds ratios <1 favor the intervention specified in the row. The table can be
downloaded as a .csv file by clicking on “Download league table” in “Configuration.”
Abbreviations: ACE, angiotensin‐converting‐enzyme inhibitors; ARB, angiotensin‐receptor blockers; CCB, calcium‐channel blocker.
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effects—are colored according to the level of concern, and judgments
under each of the three rules are also given in the boxes. Manual
change of judgments independently of the applied selection rule is
possible; if a judgment is manually changed, the corresponding box is
colored gray. “Reset” (the chosen rule) and “Proceed” (to “Reporting
bias”) buttons also appear.
4.1.2 | Worked example
Figure 2 shows the bar chart for the worked example. Studies at low
RoB contribute 53% in the estimation of ACE versus Beta Blockers,
43% of the contribution comes from studies at moderate RoB, and
studies at high RoB contribute the remaining 4%. These RoB con-
tributions resolve into “No concerns,” “Some concerns,” and “Major
concerns” using the “Majority RoB,” “Average RoB,” and “Highest
RoB” rules respectively. Figure 3 shows the boxes that appear in the
software showing the judgments for all relative effects.
4.2 | Reporting bias
The “Reporting bias” domain refers to biases that can occur due to
publication bias, time‐lag bias, selective nonreporting bias, or any
other bias that renders the included studies a nonrepresentative
sample of the studies undertaken (Dickersin and Chalmers, 2011;
Stern and Simes, 1997). Two levels of judgment for reporting bias are
suggested: “suspected” and “undetected.” Completeness of the
search, considerations related to the particular field (based on
existing evidence and empirical studies), and statistical methods un-
dertaken should inform the assessment of reporting bias for each
relative treatment effect (Chaimani and Salanti, 2012; Mavridis,
Sutton, Cipriani, & Salanti, 2013; Mavridis, Welton, Sutton, &
Salanti, 2014).
To facilitate assessment of each effect separately, users can in-
itially “Set all undetected” or “Set all suspected.” They can then
change the judgment manually for those estimates that do not fall
into the category initially assigned. Note that a manual change from
“Suspected” to “Undetected” and vice versa is not considered a de-
viation from the rule (and relevant boxes are not colored gray) as no
rule for reporting bias is implemented. “Reset” and “Proceed” (to the
“Indirectness” domain) buttons appear after initial population of
judgments. We plan to develop the “Reporting bias” domain of
CINeMA further in the months and years to come.
4.3 | Indirectness
For the indirectness domain, similar to “Within‐study bias,” the
summary shows how many studies have been characterized as of low,
moderate, and high indirectness at the top of the page. Subsequently,
a bar graph shows the contribution of studies at each indirectness
level to each NMA estimate. As for the “Within‐study bias” domain,
users can select between “Majority,” “Average,” and “Highest” rules
to summarize indirectness for each relative effect estimate. Areas are
colored accordingly, while judgments under each rule are shown in
the boxes. Manual changes can be made, and “Reset” and “Proceed”
(to the “Imprecision” domain) buttons appear.
F IGURE 2 Risk of bias bar chart for the network meta‐analysis of antihypertensive drugs and diabetes incidence. Each bar represents the
evidence for a relative treatment effect. White vertical lines separate colored areas which refer to the contribution of each study. Each bar
shows the percentage contribution from studies judged to be at low (green), moderate (yellow), and high (red) risk of bias. The plot can be
downloaded as a .png file by clicking on “Save Chart” in “Within‐study bias.” ACE, angiotensin‐converting‐enzyme inhibitors; ARB, angiotensin‐
receptor blockers; CCB, calcium‐channel blocker
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4.4 | Imprecision
In the CINeMA framework, imprecision is assessed by 95% con-
fidence intervals which may include values that could lead to dif-
ferent clinical conclusions. The calculation of 95% confidence
intervals uses the variances of the treatment effects, estimated
using maximum likelihood methods, and assumes that treatment
effects approximately follow the normal distribution. To judge
“Imprecision,” users are asked to define a clinically important size of
effect on the scale of the selected effect measure. After pressing
“Set,” the range of values to be considered as clinically important
appear. The clinically important value and its reciprocal value se-
parate the range of effects into three sets. Between them are effect
sizes that favor neither of the compared interventions; on the left
and right sides of the two clinically important values one of the two
compared interventions is favored. Note that the observed point
estimate favors one of the two interventions unless it is exactly on
the no‐effect line.
The rules for judging imprecision are based on whether the
confidence interval includes the line of no‐effect and the clinically
important values. If the confidence interval crosses the line of no‐
effect and extends to values that favor the opposite intervention to
that favored by the point estimate, “Major concerns” is assigned
(Figure 4a). If only the null effect is included in the confidence in-
tervals (and potentially also the clinically important value that favors
the same intervention as the point estimate), “Some concerns” is
assigned. Finally, “No concerns” is assigned to confidence intervals
that only include the clinically important value that favors the same
intervention as the point estimate. If the confidence interval lies
entirely between the two clinically important values, “No concerns” is
assigned (Figure 4a).
After defining the clinically important size of effect, the boxes of
the relative treatment effects appear colored according to the de-
fault rules described above. Boxes display the 95% (Wald‐type)
confidence intervals of the NMA effect, a description of its relation to
the clinically important effects, and the judgment, which can be
manually altered. Users can also reset the definition of the clinically
important size of effect and/or the imprecision judgments with the
relevant buttons. The “Proceed” button leads the user to the
“Heterogeneity” domain.
4.4.1 | Worked example
For illustration, we choose an odds ratio of 1.2 as clinically important
and CINeMA informs us that “relative effect estimates below 0.83
and above 1.2 are considered clinically important.” The confidence
interval for the comparison between diuretics and placebo ranges
from 1.12 to 1.57, which corresponds to case 3 Figure 4a. The au-
tomatically generated judgment is “No concerns” and the explanation
reads “Confidence interval does not cross clinically important effect.”
4.5 | Heterogeneity
The importance of heterogeneity depends on the variability of effects
(beyond chance) in relation to the clinically important size of effect.
The clinically important size of effect is the same as in “Imprecision”;
if already specified it will automatically appear on the top of “Het-
erogeneity.” Otherwise, users need to specify it here; if this is the
case, it will also be copied to the “Imprecision” domain. Users can
press “Reset” to reset the clinically important effect size; note that
this will affect the “Imprecision” domain too.
CINeMA considers the agreement between confidence and
prediction intervals to assign a judgment for “Heterogeneity” for
each NMA effect. Prediction intervals provide a range within which
the true effect of a new study is likely to lie (Riley, Higgins, &
Deeks, 2011). It is calculated as μ τ μˆ + + ( ˆ)t sedfa 2 2 where μˆ is the
NMA treatment effect, μ( ˆ)se its standard error and tdfa the
( − )100 1 %a
2
percentile of the t dustribution with df degrees of
F IGURE 3 Boxes showing the judgments for within‐study bias for all relative effects in the network meta‐analysis of antihypertensive drugs
and diabetes incidence. ACE, angiotensin‐converting‐enzyme inhibitors; ARB, angiotensin‐receptor blockers; CCB, calcium‐channel blocker
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freedom. We judge the agreement of conclusions based on con-
fidence and prediction intervals in relation to the null effect and the
clinically important effect on the opposite direction to the point es-
timate Our judgments based on a hypothetical, clinically important
odds ratio of 0.8 are summarized and illustrated in Table 4 and in
Figure 4a. The automatically produced judgments are shown in
boxes. Each box includes the confidence and the prediction interval, a
description of their relation to the clinically important effects, and
the assigned judgment. The latter can be manually updated.
The estimated value of common between‐study variance τ2 is also
displayed above the boxes but does not affect automated judgments. It
is possible to view “Between‐study variance estimates for each direct
comparison along with reference intervals.” To view these, users need
to select the types of intervention and outcome and press “View.”
Boxes for each relative treatment effect are then updated to include
between‐study heterogeneity measures based on direct comparisons
(I2 and τ2) and reference values for τ2 (first quantile, median, and third
quantile). The reference quantiles are taken from empirical studies and
are specific to the type of outcome and comparison (Rhodes, Turner, &
Higgins, 2015; Turner, Davey, Clarke, Thompson, & Higgins, 2012).
Reference quantiles that are lower than the estimated direct τ2 appear
in black digits and reference values greater than the estimated τ2
appear in gray digits. The comparison with the reference values does
not affect judgments. However, their critical appraisal may lead to
changing the automatically generated judgments manually.
4.5.1 | Worked example
An odds ratio of 1.2 (and 0.83) has already been specified as clinically
important. CINeMA reports that “The estimated value of between‐
study variance for the network meta‐analysis is 0.016.” The comparison
of beta blockers with placebo is judged as case 3 Figure 4a. In particular,
“Some concerns” for heterogeneity are assigned, as the confidence in-
terval (1.05–1.46) lies above the interval (0.83–1) while the prediction
interval (0.90–1.70) crosses 1. “Prediction interval extends into clinically
important or unimportant effects” is given as an explanation in the
respective box. Selecting the intervention type (pharmacological for all
interventions apart from placebo) and outcome type (semiobjective),
boxes are updated to include extra information on heterogeneity
(Turner et al., 2012). Figure 5 shows the box that appears in the soft-
ware referring to the comparison of beta blockers with placebo.
4.6 | Incoherence
The range of clinically important effects is also considered in the
“Incoherence” domain; resetting it using the “Reset” button will
F IGURE 4 Illustration of rules to assess imprecision (a),
heterogeneity (b), and incoherence (c) in CINeMA. We assume several
fictional scenarios for the odds ratio from NMA comparing
interventions X and Y. The clinically important effects were set at 0.8
and 1.25 ( = 1/0.8). The gray areas represent values that favor neither
of the competing interventions. The shaded interval represents the
interval between the null effect and clinically important size of effect.
Black horizontal lines indicate confidence intervals and red extensions
indicate prediction intervals of NMA relative treatment effects.
Dotted lines represent direct and dashed lines represent indirect
confidence intervals. Judgments are the same for cases symmetrical to
those illustrated. NMA, network meta‐analysis
TABLE 4 Summary of implemented rules for heterogeneity based on the agreement of conclusions between confidence and prediction
intervals
Number of crossings of the interval formed by the null effect and the clinically important value
that favors the opposite intervention as the point estimate
Prediction intervals
0 1 2
Confidence intervals 0 No concerns Some concerns Major concerns
1 NA No concerns Some concerns
2 NA NA No concerns
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affect “Imprecision” and “Heterogeneity” judgments. Incoherence
refers to the disagreement between direct and indirect evidence,
also called inconsistency in the literature. Several methods have
been suggested to assess disagreement statistically (Dias
et al., 2013; Dias, Welton, Caldwell, & Ades, 2010; Higgins
et al., 2012; White, Barrett, Jackson, & Higgins, 2012). CINeMA
performs and displays the results of two methods; the first is a
global method to assess incoherence, the design‐by‐treatment in-
teraction test (Higgins et al., 2012; White et al., 2012). Its results
( χ2, degrees of freedom, and p value) are shown on the top of the
“Incoherence” page. In each box, the results of the second method,
Separating Indirect from Direct Evidence (SIDE; Dias et al., 2010),
are shown, including the relative effect estimate, the direct effect,
the indirect effect, the measure of their agreement, and the re-
spective p value. As SIDE approach refers to the disagreement
measure between direct and indirect evidence as “inconsistency
factors,” we also use this terminology. Inconsistency factors
measure the disagreement between direct estimates, estimated
from studies directly comparing the particular comparison, and
indirect estimates, estimated from a NMA including all but the
direct studies. Inconsistency factors are given as the ratio of direct
and indirect effects if a ratio measure is used, or as a difference
otherwise.
The rules used to produce automatic judgments are as follow:
(1) Effect estimates based on both direct and indirect evidence and with
a p value from SIDE greater than 0.10 are assigned “No concerns.”
(2) To assign judgments for effect estimates with both direct and
indirect evidence and with a p value from SIDE <0.10, areas a, b,
and c are defined as illustrated in Figure 4a (below, within, and
above the clinically important effects). The confidence intervals
for the direct and indirect evidence are then compared with
these areas and incoherence judged according to Table 5.
Figure 4c illustrates six examples of such judgments.
(3) Effect estimates based only on direct evidence or indirect evi-
dence are assigned a judgment determined by the p value of the
design‐by‐treatment interaction test: if the p value is <0.05 then
“Major concerns,” if between 0.05 and 0.10 then “Some con-
cerns,” otherwise “No concerns.” If the design‐by‐treatment in-
teraction test is not estimable (because the network does not
have any closed loop of evidence) then “Major concerns” are
assigned to all comparisons.
As with other domains, judgments can be updated manually and
a “Reset” and “Proceed” (to “Report”) button appear if clinically im-
portant size of effect is set.
4.6.1 | Worked example
As in case 5 of Figure 4c, “Some concerns” apply to the ACE in-
hibitor versus Beta Blockers comparison with respect to “In-
coherence.” Confidence intervals of both direct (0.68–1.03) and
indirect (0.49–0.75) treatment effects extend below the clinically
important effects zone, only the direct effect's confidence interval
lies within the (0.83–1.2) interval and none extend above 1.2; thus,
direct and indirect treatment effects do not have substantial, but
only minor disagreement (Table 5). Figure 6 shows the boxes that
appear in the software showing the judgments for all relative ef-
fects for “Incoherence.”
5 | DISPLAYING JUDGMENTS FOR ALL SIX
DOMAINS: REPORT
The “Report” page brings together all the judgments for the six do-
mains across all evaluated treatment effects. Relative effects in-
formed by only direct or both direct and indirect evidence are shown
F IGURE 5 Boxes showing the information for judging
heterogeneity for the relative effect of beta blockers versus placebo
in the network meta‐analysis of antihypertensive drugs and diabetes
incidence
TABLE 5 Summary of implemented rules for incoherence based
on the agreement of direct and indirect estimates with their 95%
confidence intervals in the areas defined in Figure 4c
Common areas Incoherence judgment
0 Major concerns
1 Major concerns
2 Some concerns
3 No concerns
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first, followed by relative effects informed only by indirect evidence.
A thick gray left border line appears for judgments whose auto-
matically generated judgments have been manually modified. Users
can visit the “Report” page as soon as at least one domain has been
assessed. If users wish to summarize judgments across domains, the
“Confidence rating” dropdown menu can be used to manually assign
an overall level of confidence to each relative effect. The default
judgment is “High” confidence; downgrading by one, two, or three
levels will lead to a confidence rating of “Moderate,” “Low,” or “Very
low” respectively. We recommend considering judgments on differ-
ent domains jointly rather than in isolation (Nikolakopoulou
et al., 2019; Salanti et al., 2014). For example, “Indirectness” and
“Incoherence” domains are closely related, as they both refer to
considerations of similarity across included studies which could or
F IGURE 6 Boxes showing the judgments for incoherence for all relative effects in the network meta‐analysis of antihypertensive drugs and
diabetes incidence. ACE, angiotensin‐converting‐enzyme inhibitors; ARB, angiotensin‐receptor blockers; CCB, calcium‐channel blocker
F IGURE 7 Final output of CINeMA for the network of antihypertensive drugs and incidence of diabetes. The table shows the level of
concern for each of the six domains for each comparison and can be downloaded as a .csv file by clicking on “Download Report” in “Report.”
ACE, angiotensin‐converting‐enzyme inhibitors; ARB, angiotensin‐receptor blockers; CCB, calcium‐channel blocker
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could not manifest statistically in the data. “Imprecision” and “Het-
erogeneity” are also related as big heterogeneity will also affect the
precision of relative treatment effects. By clicking “Reset” all judg-
ments are set to “High.” Users can also download the final report as
a .csv file by clicking on “Download report.”
5.1 | Worked example
The report of the judgments for the Elliot et al. network is shown in
Figure 7. Note that some of the choices are made for the sake of
illustration only; for example, indirectness data are fictional, report-
ing bias judgments are illustrative, and the clinically important odds
ratio of 1.2 is not justified by clinical or epidemiological reasoning. A
thick gray left border appears for the judgment of indirectness for
the comparison of ACE versus CCB inhibitors as the judgment was
manually changed.
6 | DISCUSSION
We have outlined how CINeMA software can be used to facilitate
evaluation of results of NMA. Such an evaluation is an important but
challenging part of a systematic review with multiple interventions.
CINeMA, with semiautomation of methods via a guided on‐line
process greatly simplifies this process, particularly for large net-
works. CINeMA is freely available and open‐source and no login is
required. It is largely based on the methodological framework de-
scribed previously (Nikolakopoulou et al., 2019; Salanti et al., 2014).
While the main guiding principles of the CINeMA framework have
been established (Nikolakopoulou et al., 2019; Salanti et al., 2014),
specific methods, recommendations, and implementation of auto-
mated rules in CINeMA software are evolving.
Important platform updates will follow. These include users
being able to upload multiple projects they are working on con-
currently. With the addition of this feature, users will be able to also
have multiple outcomes per project, something that is currently not
supported by CINeMA. Note, however, that dependency between
outcomes will not be assessed. Users will also be able to download a
league table with studies of only low, or only low and moderate RoB
(or indirectness). The “Report” page will be updated so that users can
click on each comparison by domain judgment and decide whether
they will downgrade their confidence or not, and if yes, for one or
two levels.
Subjectivity is inevitable in any process or system evaluating
evidence, and CINeMA is no exception. Several aspects of the eva-
luations such as interpretation of heterogeneity and definition of a
clinically important size of effect are clearly subjective. A study to
examine CINeMA's reproducibility by measuring the agreement be-
tween assessments made by researchers using CINeMA would be of
interest. The clearly defined criteria on which judgments are based
should increase reproducibility and the fact that CINeMA is open‐
source ensures transparency.
Evidence synthesis is used by organizations to take decisions
about whether to reimburse a medicinal product, by clinical guideline
panels to recommend one drug over another, and by clinicians to
prescribe an intervention or recommend a diagnostic procedure.
CINeMA is a transparent framework to evaluate evidence from
systematic reviews with multiple interventions, and we hope that the
software presented here will facilitate its uptake.
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